Intravascular Large B-Cell Lymphoma: A Difficult Diagnostic Challenge

Maria S. Khan, MD, FACP, Mark McCubbin, MD, and Sucha Nand, MD

Abstract

Case Presentation. A 69-year-old Hispanic male, with a past history of diabetes and coronary disease, was admitted for fever, diarrhea, and confusion of 4 weeks duration. Physical examination showed a disoriented patient with multiple ecchymoses, possible ascites, and bilateral scrotal swelling. Hemoglobin was 6.7, prothrombin time (PT) 21.4 seconds with international normalized ratio 2.1, partial thromboplastin time (PTT) 55.6 seconds, fibrin split 10 µg/L, and lactate dehydrogenase (LDH) 1231 IU/L. Except for a positive DNA test for Epstein–Barr virus (EBV) infection, extensive diagnostic workup for infections, malignancy, or a neurological cause was negative. Mixing studies revealed a nonspecific inhibitor of PT and PTT but Factor VIII levels were normal. The patient was empirically treated with antibiotics but developed hypotension and died on day 27 of admission. At autopsy, patient was found to have intravascular diffuse large B-cell lymphoma involving skin, testes, lung, and muscles. The malignant cells were positive for CD20, CD79a, Mum-1, and Pax-5 and negative for CD3, CD5, CD10, CD30, and Bcl-6. The malignant cells were 100% positive for Ki-67. Discussion. Intravascular large cell B-cell lymphoma (IVLBCL) is rare form of diffuse large B-cell lymphoma and tends to proliferate within small blood vessels, particularly capillaries and postcapillary venules. The cause of its affinity for vascular bed remains unknown. In many reports, IVLBCL was associated with HIV, HHV8, and EBV infections. The fact that our case showed evidence of EBV infection lends support to the association of this diagnosis to viral illness. The available literature on this subject is scant, and in many cases, the diagnosis was made only at autopsy. The typical presentation of this disorder is with B symptoms, progressive neurologic deficits, and skin findings. Bone marrow, spleen, and liver are involved in a minority of patients. Nearly all patients have elevated LDH, and about 65% are anemic. About 20% have hepatic and renal dysfunction. The treatment consists of systemic chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone plus rituximab (CHOP-R) and central nervous system prophylaxis. Retrospective data suggests that, with treatment, 51% to 82% of the patients achieve a complete remission and 27% to 56% are alive at 2-year follow-up. Conclusion. IVLBCL is a difficult diagnosis to make as the disease remains confined to the vascular lumen. It may be associated with certain viral illnesses, and this association needs to be explored further. It is important to consider this diagnosis in the appropriate settings because patients may achieve durable remissions with therapy.

Keywords

B cell, lymphoma

Background

Intravascular large cell B-cell lymphoma (IVLBCL) is a malignancy confined to the lumina of small blood vessels without any extravascular tumor mass or circulating lymphoma cells in the peripheral blood or bone marrow.2 IVLBCL is rare, and as of 2007, only about 300 cases have been reported, mostly involving B cells (IVLBCL). We report a case of IVLBCL in a patient presenting as fever of unknown origin.

Case Presentation

A previously healthy 69-year-old Hispanic male presented with fever, diarrhea, anasarca, and confusion during the past 4 weeks. Physical examination showed a disoriented patient with multiple ecchymoses, ascites, scrotal swelling, and lower extremity edema. Hospital course was complicated by worsening renal failure, increasing oxygen requirements, spontaneous retroperitoneal bleed, and lactic acidosis. The patient was empirically treated with broad-spectrum antibiotics but developed altered mental status and circulatory collapse. He was transferred to the intensive care unit after developing respiratory failure and shock. He was intubated and placed on mechanical ventilation and started on vasopressor support. The patient subsequently expired on hospital day 27.

1The Ohio State University Medical Center, Columbus Ohio
2Loyola University Medical Center, Maywood, Illinois

Corresponding Author:
Maria S. Khan 395 West 12th Avenue, Columbus, OH 43210, USA
Email: Maria.Khan@osumc.edu
Methods and Findings

Laboratory studies on admission showed white blood cell count 3800 µL with 62% segs and 24% lymphocytes, hemoglobin 6.7 g/dL, platelet count 117 × 106/µL, blood urea nitrogen 44 mg/dL, creatinine 2.0 mg/dL, prothrombin time (PT) 21.4 seconds, international normalized ratio (INR) 2.1, partial thromboplastin time (PTT) 55.6 seconds, fibrinogen 592 mg/dL, fibrin split products 10 µg/L, and lactate dehydrogenase (LDH) 1231 IU/L. Mixing studies corrected the PT but not PTT. Factor VIII levels were normal. Total bilirubin was 1.0 mg/dL, direct bilirubin 0.4 mg/dL, haptoglobin level was normal at 73, aspartate aminotransferase 53 U/L (14-45 U/L), and alanine aminotransferase 17 U/L (15-40 U/L). Except for a positive DNA test for Epstein–Barr virus (EBV) infection, an extensive diagnostic workup for infections (HIV, arbo virus, viral hepatitis, quantiferon gold, histoplasma antigen, bacterial, fungal, AFB, pleural fluid analysis), malignancy (computed tomography scan of brain, chest, abdomen, pelvis, scrotal ultrasound, bone marrow biopsy), rheumatic diseases (ANA, ANCA, and C3/C4), and neurological causes (lumbar puncture) was negative. EBV was positive. Gallium scan showed uptake in the lung and groin but no focal lesions. At autopsy, he was found to have intravascular diffuse large B-cell lymphoma involving skin, testes, lung, and muscles (see Figure 1). The malignant cells were positive for CD20, CD791, Mum-1, and Pax-5 and negative for CD3, CD5, CD10, CD30, and Bcl-6. The malignant cells were 100% positive for Ki-67.

Discussion

This patient died of a rare variant of diffuse large B-cell lymphoma, also known as angiotropic large cell lymphoma, was first described in 1959 by Pfleger and Tappeiner. It was formerly known as “malignant angioendotheliomatosis.” It is a rare subtype of extranodal diffuse large B-cell lymphoma resulting from proliferation of neoplastic mononuclear cells within small blood vessels, particularly capillaries and postcapillary venules. The neoplastic cells are usually of B-cell origin but rarely can be T-cell or histiocytic derivation. The cause of its affinity for the vascular bed remains unknown. In many reports, IVLBC is associated with HIV, HHV8, and EBV infections. It occurs primarily in adults (median age 67 years), with male-to-female ratio of 1:1.

The most commonly involved sites in this lymphoma are skin and brain, but it can involve any organ. It has 2 major subtypes: “Western” subtype with skin and neurologic involvement and “Asian” subtype that presents as a hemophagocytic syndrome with multiorgan involvement. A “cutaneous” variant has also been described wherein the disease remained confined to the skin and has a favorable prognosis.

The typical presentation of this disorder is with B symptoms (fever, night sweats, and weight loss); progressive neurologic deficits, such as dementia, headaches, seizures, and focal deficits; and skin lesions, which have been described as red, tender plaques or ulcerations mostly on lower extremities with edema. The skin lesions can be misinterpreted as thrombophlebitis, erythema nodosum, or erysipelas.

Diagnosis is made when large lymphoma cells are seen within small to medium-sized blood vessels. This often requires obtaining multiple skin or other biopsies. In general, the IVLBC does not involve bone marrow, lymph nodes, peripheral blood, and cerebrospinal fluid. The role of imaging is limited, as the tumor does not present as a mass lesion. Similarly, positron emission tomography scan, normally a useful tool in diagnosis and monitoring of lymphomas, has a limited role in IVLBC unless the patient has central nervous system (CNS) involvement.

Treatment consists of systemic chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone plus rituximab (CHOP-R) and CNS prophylaxis. Retrospective data suggests that, with treatment, 51% to 82% of the patients achieve a complete remission and 27% to 56% are alive at 2-year follow-up.

Untreated IVLBC has an extremely aggressive course and poor prognosis, with a median survival of 5 months.

Conclusion

Look for uncommon variants and locations of the suspected disorder when the data suggest a particular diagnosis. In this patient, a high LDH level suggested a hematologic malignancy as other possibilities had been ruled out. Even though all his biopsies were negative for lymphoma even on retrospective review, a more extensive examination may have yielded the diagnosis of a potentially curable disease.
Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

1. Shimada K, Kinoshita T, Naoe T, Nakamura S. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol. 2009;10:895-902.
2. Bhawan J, Wolff SM, Ucci AA, Bhan AK. Malignant lymphoma and malignant angioendotheliomatosis: one disease. Cancer. 1985;55:570-576.
3. Pfleger L, Tappeiner J. On the recognition of systematized endotheliomatosis of the cutaneous blood vessels (reticuloendotheliosis). Hautarzt. 1959;10:359-363.
4. Kiyohara T, Kumakiri M, Kobayashi H, Shimizu T, Ohkawara A, Ohnuki M. A case of intravascular large B-cell lymphoma mimicking erythema nodosum: the importance of multiple skin biopsies. J Cutan Pathol. 2000;27:413-418.
5. Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood. 2007;109:478-485.
6. Bogomolski-Yahalom V, Lossos IS, Okun E, Sherman Y, Lossos A, Polliack A. Intravascular lymphomatosis—an indolent or aggressive entity? Leuk Lymphoma. 1998;29:585-593.
7. Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
8. Chapin JE, Davis LE, Kornfeld M, Mandler RN. Neurologic manifestations of intravascular lymphomatosis. Acta Neurol Scand. 1995;91:494-499.
9. Glass J, Hochberg FH, Miller DC. Intravascular lymphomatosis. A systemic disease with neurologic manifestations. Cancer. 1993;71:3156-3164.
10. Permicario C. Unusual cutaneous lymphomas. Dermatol Surg. 1996;22:288-292.
11. Roglin J, Boer A. Skin manifestations of intravascular lymphoma mimic inflammatory diseases of the skin. Br J Dermatol. 2007;157:16-25.
12. Shimada K, Murase T, Matsue K, et al. Central nervous system involvement in intravascular large B cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci. 2010;101:1480-1485.
13. Yamada S, Nishii R, Oka S, et al. FDG-PET a pivotal imaging modality for diagnosis of stroke-onset intravascular lymphoma. Arch Neurol. 2010;67:366-371.
14. Shimada K, Matsue K, Yamamoto K, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol. 2008;26:3189-3195.
15. Ponzoni M, Ferreri AJ, Campo E, et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol. 2007;25:3168-3173.
16. Domizio P, Hall PA, Cotter F, et al. Angiotropic large cell lymphoma (ALCL): morphological, immunohistochemical and genotypic studies with analysis of previous reports. Hematol Oncol. 1989;7:195-206.
17. Dufau JP, Le Tourneau A, Molina T, et al. Intravascular large B-cell lymphoma with bone marrow involvement at presentation and haemophagocytic syndrome: two Western cases in favour of a specific variant. Histopathology. 2000;37:509-512.